Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Gains from Sales and Divestitures: 2019-2023

Historic Gains from Sales and Divestitures for Bicycle Therapeutics (BCYC) over the last 3 years, with Dec 2023 value amounting to $119,144.

  • Bicycle Therapeutics' Gains from Sales and Divestitures rose 240.41% to $119,144 in Q4 2023 from the same period last year, while for Dec 2023 it was $119,144, marking a year-over-year increase of 240.41%. This contributed to the annual value of $119,144 for FY2023, which is 240.41% up from last year.
  • According to the latest figures from Q4 2023, Bicycle Therapeutics' Gains from Sales and Divestitures is $119,144, which was up 19.58% from $99,638 recorded in Q3 2023.
  • Bicycle Therapeutics' Gains from Sales and Divestitures' 5-year high stood at $119,144 during Q4 2023, with a 5-year trough of $35,000 in Q1 2022.
  • For the 2-year period, Bicycle Therapeutics' Gains from Sales and Divestitures averaged around $61,819, with its median value being $45,994 (2022).
  • Data for Bicycle Therapeutics' Gains from Sales and Divestitures shows a peak YoY surged of 240.41% (in 2023) over the last 5 years.
  • Bicycle Therapeutics' Gains from Sales and Divestitures (Quarterly) stood at $83,947 in 2019, then reached $35,000 in 2022, then skyrocketed by 240.41% to $119,144 in 2023.
  • Its last three reported values are $119,144 in Q4 2023, $99,638 for Q3 2023, and $78,781 during Q2 2023.